
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Synteract, a CRO, has acquired KinderPharm, a pediatric CRO, focused on advancing pediatric drug development across all phases of clinical research. Together, Synteract and KinderPharm will deliver a single source model for preclinical and clinical development, along with the operational and logistical understanding required in working with children and their families.
Read the full release






